Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2 …
M Verdoia, H Suryapranata, S Damen… - Journal of Thrombosis …, 2021 - Springer
Background Gender differences in the thrombotic and bleeding risk have been suggested to
condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) …
condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) …
Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual …
E Kedhi, M Verdoia, H Suryapranata, S Damen… - Atherosclerosis, 2021 - Elsevier
Background and aims The impact of advanced age on the optimal duration of dual
antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing …
antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing …
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and …
C Camaro, SAJ Damen, MA Brouwer, E Kedhi… - American Heart …, 2016 - Elsevier
Background The optimal duration of dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) patients treated with drug eluting stents (DES) is still under debate. Recent …
syndrome (ACS) patients treated with drug eluting stents (DES) is still under debate. Recent …
[PDF][PDF] Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent …
G De Luca, SA Damen, C Camaro, E Benit… - …, 2019 - academia.edu
Aims: The optimal duration of DAPT in ACS patients treated with DES is still unclear.
Therefore, the aim of the current study was to investigate a short versus a standard 12-month …
Therefore, the aim of the current study was to investigate a short versus a standard 12-month …
Duration of dual antiplatelet therapy in patients with acute coronary syndrome treated with new generation stents: a meta-analysis of randomized controlled trials
WJ Zhang, X Qiao, WF Guo, XY Liang, Y Li… - Frontiers in …, 2021 - frontiersin.org
Background and Objective: The optimum duration of dual antiplatelet therapy (DAPT)
remains uncertain in patients with acute coronary syndrome treated with new generation …
remains uncertain in patients with acute coronary syndrome treated with new generation …
Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized …
Among patients who have undergone percutaneous coronary intervention (PCI), the use of
dual antiplatelet therapy (DAPT) is associated with increased risk of bleeding, but decreased …
dual antiplatelet therapy (DAPT) is associated with increased risk of bleeding, but decreased …
Meta-analysis of duration of dual antiplatelet therapy in acute coronary syndrome treated with coronary stenting
We aimed to evaluate if a shorter course of DAPT followed by P2Y12 inhibitor monotherapy
is as effective as a 12-month course with fewer bleeding events. PubMed, Scopus, and …
is as effective as a 12-month course with fewer bleeding events. PubMed, Scopus, and …
Efficacy and safety of short-term 1–3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta …
WJ Zhang, X Qiao, XY Liang, Y Li, RR Yang, ZL Wang - Platelets, 2021 - Taylor & Francis
Dual antiplatelet therapy (DAPT) is the basis of preventing stent thrombosis and ischemic
events after percutaneous coronary intervention (PCI), but prolonging the duration of DAPT …
events after percutaneous coronary intervention (PCI), but prolonging the duration of DAPT …
Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
Background Although dual antiplatelet therapy (DAPT) improves the outcomes of patients
undergoing percutaneous coronary intervention (PCI), sex-specific differences in efficacy …
undergoing percutaneous coronary intervention (PCI), sex-specific differences in efficacy …
Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 …
M Verdoia, E Khedi, C Ceccon, H Suryapranata… - International Journal of …, 2018 - Elsevier
Background Acute coronary syndromes (ACS) represent a context of higher thrombotic risk,
where larger advantages have been achieved by the administration of dual antiplatelet …
where larger advantages have been achieved by the administration of dual antiplatelet …